The liver fibrosis market is growing due to increasing prevalence of chronic liver conditions, including hepatitis and non-alcoholic fatty liver disease (NAFLD), along with improvements in non-invasive diagnostic methods. Key companies like Madrigal Pharmaceuticals, Akero Therapeutics, Sagimet Biosciences, and 89bio are advancing therapies targeting fibrotic pathways. Market expansion is supported by rising awareness, earlier diagnosis, and the development of more effective treatment options. Access Market Report: https://shorturl.at/7M2K7